Do you want to read an article? Please log in or register.
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
Type 2 Diabetes
Related content
COMMENTED
Type 1 Diabetes
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.1111/dom.14060.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Diabetes Care.
Jabbour SA, Frìas JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C
doi: 10.2337/dc18-0680.
COMMENTED
Type 2 Diabetes
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Lancet.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A
doi: 10.1016/S0140-6736(18)32260-8.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Lancet Diabetes Endocrinol.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC
doi: 10.1016/
Type 2 Diabetes
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Lancet Diabetes Endocrinol.
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y, PIONEER 9 investigators.
doi: 10.1016/S2213-8587(20)30075-9.
COMMENTED
Diabetes - GeneralType 2 Diabetes
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
Diabetes Care.
Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR
doi: 10.2337/dc17-2381.
Glycemic Control
Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial
Diabetes Care.
Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF
doi: 10.2337/dc17-0374.
COMMENTED
Type 1 DiabetesGlycemic Control
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Diabetes Care.
Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators
doi: 10.2337/dc18-1087.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study
Diabetes Obes Metab.
Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A
doi: 10.1111/dom.13473.